Can the LANSS scale be used to classify pain in chronic cancer pain trials?

Hardy, Janet, Quinn, Stephen, Fazekas, Belinda, Aga, Meera and Currow, David (2013) Can the LANSS scale be used to classify pain in chronic cancer pain trials?. Supportive Care in Cancer, 21 12: 3387-3391. doi:10.1007/s00520-013-1921-5

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Hardy, Janet
Quinn, Stephen
Fazekas, Belinda
Aga, Meera
Currow, David
Title Can the LANSS scale be used to classify pain in chronic cancer pain trials?
Journal name Supportive Care in Cancer   Check publisher's open access policy
ISSN 0941-4355
1433-7339
Publication date 2013
Year available 2013
Sub-type Article (original research)
DOI 10.1007/s00520-013-1921-5
Open Access Status Not Open Access
Volume 21
Issue 12
Start page 3387
End page 3391
Total pages 5
Place of publication Heidelberg, Germany
Publisher Springer
Collection year 2014
Language eng
Subject 2730 Oncology
Abstract Purpose: The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale was developed to differentiate pain of predominantly neuropathic or nociceptive origin. The aim of this study was to determine whether the LANSS scale was an appropriate tool to classify pain in a trial of patients with advanced cancer and chronic refractory pain. Methods: Clinician assessment of pain type (neuropathic or nociceptive) was used to determine the sensitivity and specificity of LANSS scores in 112 trial participants. Those classified as "mixed" or of uncertain aetiology were excluded. We undertook several analyses in an attempt to improve the LANSS scale and better diagnose pain type for our specific dataset. Results: There was strong association between the LANSS score and a diagnosis of neuropathic versus nociceptive pain, p < 0.001. When the clinical assessment was compared with the LANSS scale, the overall accuracy was 94 % (79/84). The 5 false negatives and no false positives resulted in a sensitivity of 0.86 (0.70, 0.95), specificity of 1 (0.93, 1), positive predictive value of 1 (0.88, 1) and negative predictive value of 0.91 (0.80, 0.97). The negative likelihood ratio was 0.14 (0, 0.32). The scale had good discriminant and construct validity. Reliability was assessed via internal consistency with Cronbach's α = 0.76, similar to that of the original validation study (α = 0.74). None of the new scales developed was better at differentiating pain type. Conclusions: The LANSS scale predicted well for pain type in a cancer population and is a useful tool for classifying pain in cancer pain trials.
Keyword Cancer
LANSS scale
Neuropathic pain
Pain trials
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 24 Apr 2014, 14:07:53 EST by Dominique Rossouw on behalf of Medicine - Mater Hospital